Molecular characterization of gastric adenocarcinoma diagnosed in patients previously treated for Hodgkin lymphoma or testicular cancer

Lisanne S. Rigter1, Petur Snaebjornsson2, Efraim H. Rosenberg2, Estelle Altena1, Nicole C. T. van Grieken3, Bertram P. Aleman4, Jan M. Kerst5, Lindsay Morton6, Michael Schaalpveid7, Gerrit A. Meijer2, Flora E. van Leeuwen7, Monique E. van Leerdam1*, PALGA group9

1 Department of Gastroenterology, Netherlands Cancer Institute, Amsterdam, The Netherlands, 2 Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands, 3 Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands, 4 Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands, 5 Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands, 6 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America, 7 Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands

* Membership of the PALGA group is listed in the Acknowledgments.

m.v.leerdam@nki.nl

Abstract

Introduction

The risk of developing gastric cancer is increased in patients treated with radiotherapy for Hodgkin lymphoma (HL) or testicular cancer (TC). This study aims to assess if gastric adenocarcinoma after treatment for HL/TC (t-GC) is molecularly different from gastric adenocarcinoma in the general population.

Methods

Patients were diagnosed with t-GC ≥5 years after treatment for HL/TC. Four molecular subtypes were identified using immunohistochemical and molecular analyses: Epstein-Barr virus (EBV), mismatch repair (MMR) deficiency or microsatellite instability (MSI), aberrant p53 staining as surrogate for chromosomal instability (sCIN), and a surrogate for genomic stability (sGS) without these aberrations. Results were compared with gastric cancer in the general population (p-GC) described in literature.

Results

Molecular subtyping of 90 t-GCs resulted in 3% EBV, 8% MSI, 36% sCIN and 53% sGS. 3/6 of MSI t-GCs had MLH1 promoter methylation and 2/6 were explained by double somatic mutations in MMR genes. T-GCs were more frequently sGS than p-GCs (53% vs. 38%, p = 0.04). T-GC was more frequently sGS in HL/TC patients diagnosed before 1990, than after...
1990 (63% vs. 38%, \( p = 0.03 \)). T-GCs located in the antrum, an area that receives high irradiation doses, were more frequently sGS (61% vs. 28% in p-GCs, \( p = 0.02 \)).

**Conclusion**

Our results demonstrate that t-GCs are more frequently of the sGS subtype than p-GCs. An association of t-GC of the sGS subtype with prior anticancer treatment is suggested by the high frequency in HL/TC patients who were treated before 1990, a time period in which HL/TC treatments were more extensive.

**Introduction**

The risk of developing gastric cancer is increased in survivors of Hodgkin lymphoma and testicular cancer [1–16]. Compared with the general population, 2- to 13-fold increased risks have been reported, which persist up to 40 years after primary cancer treatment [5, 11]. In survivors of both Hodgkin lymphoma and testicular cancer, prior treatment with abdominal radiotherapy is strongly associated with the increased gastric cancer risk [2, 3, 9–11]. In Hodgkin lymphoma survivors, the alkylating agents procarbazine and possibly dacarbazine are also associated with the increased risk of gastric cancer [2].

Overall survival of gastric cancer has been reported to be worse in Hodgkin lymphoma survivors compared with first primary cancer patients, which could result from patient-related factors (e.g. comorbidity or reduced treatment options due to prior cancer treatment), but may also reflect a difference in tumor biology [17].

Although several mouse models described alkylating agents, and irradiation to a lesser extent, as gastric carcinogens, the role of these treatments in the pathogenesis of gastric adenocarcinoma is unknown [18–20]. Our group previously studied therapy-related colorectal cancer in Hodgkin lymphoma survivors and demonstrated a high frequency of microsatellite instability (MSI) compared with the general population. This high MSI frequency in therapy-related colorectal cancer was not caused by \( MLH1 \) promoter methylation, which is common in sporadic colorectal cancer, but was the consequence of somatic mismatch repair (MMR) gene mutations [21]. In a small study on therapy-related esophageal cancer, however, MSI frequency was low [22].

In the general population, approximately 7–23% of gastric adenocarcinomas are MSI [23–27]. These adenocarcinomas are considered a separate molecular subtype in the classifications of The Cancer Genome Atlas Research Network (TCGA) and the Asian Cancer Research Group (ACRG) [23, 24]. Microsatellite stable gastric adenocarcinomas are further subdivided into Epstein-Barr virus (EBV)-positive (9%), chromosomally unstable (50%) and genomically stable (20%) subtypes according to TCGA [23]. The distribution of these molecular subtypes is influenced by multiple factors, including gastric cancer location, age at diagnosis and population [23, 28, 29]. As an alternative for the extensive molecular characterization used by both TCGA and ACRG, surrogate molecular classifications using immunohistochemistry have been developed [25–27].

The molecular subtype distribution of gastric adenocarcinoma after treatment (t-GC) for Hodgkin lymphoma or testicular cancer is unknown. In both survivors of Hodgkin lymphoma and testicular cancer, the increased risk is associated with cancer treatment, which may result in a different pathogenesis of second primary cancers in both groups compared to sporadic gastric cancer. We hypothesize that t-GCs may have a high frequency of EBV, as 30% of
Hodgkin lymphomas are associated with EBV. A second *a priori* hypothesis is that t-GCs may have a high frequency of chromosomal instability due to the effects of radiotherapy. Finally, a high frequency of MSI caused by somatic MMR gene mutations may be present, as was reported in therapy-related colorectal cancer [21].

In this study, we evaluate tumor characteristics and molecular subtypes of t-GC, using a surrogate classification method that was previously reported, in order to give insight into the pattern of t-GC development [27].

**Methods**

**Patients and tissue samples**

This cohort study included patients who were diagnosed with gastric cancer at least five years after the diagnosis of Hodgkin lymphoma or testicular cancer. These patients were identified in two ways.

In the first approach, we identified patients through two Dutch multicenter cohorts of 5-year survivors, one of Hodgkin lymphoma survivors (N = 3905; treatment period 1965–2000) and one of testicular cancer survivors (N = 1029; treatment period 1965–1995) [5, 30]. Information on second cancers, including dates of diagnosis, morphologic features, topographic features and treatment, was collected by a review of medical records, by responses to questionnaires sent to general practitioners, and by record linkage with the Netherlands Cancer Registry since 1989, when the Netherlands Cancer Registry reached nationwide coverage, as described previously [5, 30–32]. The formalin-fixed paraffin-embedded (FFPE) t-GC and normal gastric tissue, and pathology reports of the t-GC patients were retrieved via the nationwide network and registry of histopathology and cytopathology in the Netherlands (PALGA) [33].

The second approach consisted of the identification of additional t-GC patients through the PALGA registry. This registry was searched for patients with a combination of firstly a Hodgkin lymphoma or testicular cancer diagnosis (seminoma or non-seminoma) and secondly a gastric adenocarcinoma diagnosis. Additionally, FFPE tissue and pathology reports of t-GCs and normal gastric tissue were requested. For treatment information on Hodgkin lymphoma and testicular cancer, local hospitals were contacted through PALGA to provide these data anonymously. Unfortunately, treatment data retrieval through this last method was limited due to low hospital participation rates and inaccessible old patient records.

This study was approved by the institutional research board of the Netherlands Cancer Institute (study number CFMPB307). The regulations of the ‘Code for Proper Secondary Use of Human Tissue in The Netherlands’, Dutch Federation of Biomedical Scientific Societies, the Netherlands were applied in collection, storage and use of patient-derived tissue and data. Thus, all data and tumor tissues were processed anonymously.

**Histopathology**

H&E stained slides were used for confirmation of the diagnosis of an adenocarcinoma in the stomach or gastroesophageal junction. As the location of adenocarcinoma biopsies of the distal esophagus, gastroesophageal junction, or cardia was poorly defined in pathology reports, and classification systems have changed over time, these tumors were defined as gastroesophageal junction tumors [34]. The reassessment of the diagnosis occurred by standard protocol and included histopathological typing according to Lauren and World Health Organization (WHO) classifications [29, 35], tumor location and tumor-node-metastasis (TNM) stage. For the assessment of distant metastases (M stage), clinical information in pathology reports and tissue samples of metastases were used when available.
**Immunohistochemistry**

Tissue microarrays (TMAs) were made if resection specimens were available and used for immunohistochemistry (IHC). When only biopsy specimens were available, whole slides were used. EBV-encoded small RNAs (EBER) in situ hybridization (ISH, INFORM EBER Probe (Roche)) staining was performed on a BenchMark Ultra autostainer (Ventana). For the evaluation of MMR proteins, IHC was performed according to standard protocols for Ventana immunostainer (MLH1 (M1, 6472966001 Roche (Ventana)), MSH2 (G219-1129, 5269270001, Roche (Ventana)), MSH6 (EP49, AC-0047, Epitomics), PMS2 (EP51, M3647, Dako)). IHC of p53 was performed using the DO-7 antibody (Dako). Diffuse, strong nuclear staining (≥70%) was interpreted as aberrant. Human epidermal receptor 2 (HER2) was evaluated by clone 4B5, Roche (Ventana). IHC HER2 scores of 2+ were further analyzed through ISH.

**Molecular analyses**

Tumor DNA and normal tissue DNA were isolated using a Qiagen extraction kit. The normal tissue used for DNA isolation included normal gastric mucosa, or adjacent normal tissues of, for example, esophagus or small intestine. DNA concentrations were measured using the Qubit 2.0 Fluorometer with the Qubit dsDNA Assay Kit. MSI was assessed by a pentaplex PCR-based assay using fluorescent labelled primers of five mononucleotide repeat targets (BAT25, BAT26, NR24, NR21, NR27), followed by fragment analysis. In case of instability in two markers or more, the tumor was defined as MSI and further analysis of promoter methylation of MMR genes was performed by multiplex ligation-dependent probe amplification (MLPA, ME011-B2 kit; MRC Holland, Amsterdam, the Netherlands). This included a total of 19 probes located at the promoter region of six different MMR genes (MLH1, MSH2, MSH6, PMS2, MSH3, MLH3). The presence of promoter methylation was defined as positivity of 33% of probes per gene with a 0.2 cut-off at probe level.

In MSI cases without MMR gene promoter methylation, MMR genes were additionally screened for mutations with the Ion Torrent Personal Genome Machine (Life Technologies, Carlsbad, CA, USA) and pathogenicity was predicted as previously described [21]. In addition, for detection of large genomic aberrations or loss of heterozygosity (LOH) of chromosomes 2, 3 and 7, primer panels for analysis of polymorphic single nucleotide polymorphisms (SNPs) were added.

**Molecular subtypes**

All adenocarcinomas were divided into four molecular subtypes, according to the method used in the general population cohort that was used for comparison [27]. This general population cohort consisted of 104 gastric adenocarcinoma patients who were diagnosed at an average age of 67 years (range 34–95 years) in the United States.

Firstly, EBER positive tumors were classified as the EBV subtype. Secondly, the MSI subtype included tumors that displayed aberrant MMR staining and/or MSI. Thirdly, strong nuclear staining of p53 was used as a surrogate for the chromosomal instability (sCIN) subtype, as they frequently have TP53 mutations [23]. The remaining cases had none of the aberrations (EBER negative, microsatellite stable, no overexpression of p53). This profile represented the fourth subtype, which is surrogate for genomic stability (sGS).

**Statistical analyses**

IBM SPSS V.22.0 database software was used to store and analyze data on patient and tumor characteristics. Frequencies of tumor characteristics were compared within subtypes using $\chi^2$
tests or Fisher’s exact tests for binary or categorical data and Kruskal Wallis tests for continuous data. In addition, these tests were performed for comparison with data from a previously published gastric cancer cohort from the general population that used similar IHC methods to define molecular subtypes [27]. The significance level was defined as two-sided \( p < 0.05 \). No adjustments were made for multiple comparisons.

**Results**

**Characteristics of patients who survived Hodgkin lymphoma or testicular cancer and developed gastric cancer**

In total 196 t-GC patients were identified. (S1 Fig) FFPE adenocarcinoma tissue was obtained from 90 (46%) t-GCs, diagnosed in 66 Hodgkin lymphoma survivors and 24 testicular cancer survivors. (Table 1) Patients were diagnosed with Hodgkin lymphoma or testicular cancer between 1967 and 2009, at a median age of 39 years (interquartile range (IQR) 27–50 years). Treatment data were available for assessment of treatment category in 43/66 (65%) of Hodgkin lymphoma survivors and 14/24 (58%) of testicular cancer survivors. In 48/57 patients with available treatment data, the treatment consisted of abdominal radiotherapy and/or the alkylating agents procarbazine or dacarbazine.

Table 1. Hodgkin lymphoma and testicular cancer characteristics of patients who developed gastric cancer.

| Primary cancer characteristics | Total N = 90 | Hodgkin lymphoma N = 66 | Testicular cancer N = 24 |
|------------------------------|-------------|-------------------------|-------------------------|
|                              | median (IQR) | median (IQR) | median (IQR) |
| Age at primary diagnosis     | 39 (27–50)  | 39 (27–52) | 44 (29–50) |
| Latency primary cancer to t-GC in years | 16 (11–22) | 16 (11–22) | 13 (9–22) |
| Year of diagnosis            |             |             |             |
| 1967–1979                    | 19 (21)     | 13 (20)     | 6 (25)      |
| 1980–1989                    | 37 (41)     | 26 (39)     | 11 (46)     |
| 1990–1999                    | 23 (26)     | 19 (29)     | 4 (17)      |
| 2000–2009                    | 11 (12)     | 8 (12)      | 3 (13)      |
| Abdominal RT                 |             |             |             |
| No                           | 19 (21)     | 15 (23)     | 4 (17)      |
| Yes                          | 37 (41)     | 27 (41)     | 10 (42)     |
| Unknown                      | 56 (38)     | 24 (36)     | 10 (42)     |
| Alkylating agents            |             |             |             |
| No                           | 30 (33)     | 16 (24)     | 14 (58)     |
| Procarbazine/dacarbazine     | 19 (21)     | 19 (29)     | 0 (0)       |
| Procarbazine                 | 4 (4)       | 4 (6)       | 0 (0)       |
| Dacarbazine                  | 37 (41)     | 27 (41)     | 10 (42)     |
| Unknown                      |             |             |             |
| Primary treatment category   |             |             |             |
| Abdominal RT—/ AA -          | 9 (10)      | 5 (8)       | 4 (17)      |
| Abdominal RT + / AA -        | 25 (28)     | 15 (23)     | 10 (42)     |
| Abdominal RT—/ AA +          | 11 (12)     | 11 (17)     | 0 (0)       |
| Abdominal RT + / AA +        | 12 (13)     | 12 (18)     | 0 (0)       |
| Unknown                      | 33 (37)     | 23 (35)     | 10 (42)     |

**Abbreviations:** t-GC, gastric cancer after treatment for Hodgkin lymphoma or testicular cancer; IQR, interquartile range; RT, radiotherapy; AA, alkylating agents (procarbazine/dacarbazine).

https://doi.org/10.1371/journal.pone.0270591.t001
Patients were diagnosed with t-GC between 1982 and 2015, at a median age of 58 years (IQR 48–69, Table 2). The majority of t-GCs was located at the gastroesophageal junction (43%) and in the antrum (including pylorus, 31%), and 19% of tumors were located in the fundus and corpus of the stomach (Fig 1). TNM stage was evaluable in 57/90 (63%) t-GCs, of which 25/57 (44%) were stage I/II and 32/57 (56%) stage III/IV. Lauren classification resulted in 51 (57%) intestinal type t-GCs, 32 (36%) diffuse type t-GCs and 7 (8%) mixed type t-GCs. The distribution of histological types according to Lauren differed significantly depending on the tumor location; 77% of gastroesophageal junction tumors were of the intestinal type while this type comprised 53% of tumors in the fundus and corpus, and 32% of tumors in the antrum ($p = 0.004$, Fig 1).

Classification of molecular subtypes in gastric cancer after treatment for Hodgkin lymphoma or testicular cancer

The molecular subtype distribution of t-GCs is described in Table 2. EBV was positive in 3/90 (3%) t-GCs. The MSI subtype (n = 7, 8%) consisted of six MSI t-GCs and one additional microsatellite stable t-GC with MMR deficiency. This latter tumor showed partly clonal loss of MLH1 and PMS2 staining and partly retained MMR staining in tumor biopsies (Table 3). Of the six MSI t-GCs, three showed a complete loss of MLH1 and PMS2 staining that was
Fig 1. Distribution of molecular subtypes and Lauren classification across locations of gastric cancer after treatment for Hodgkin lymphoma or testicular cancer. 

Abbreviations: GEJ, gastroesophageal junction; EBV, Epstein-Barr virus; MSI, microsatellite instability; CIN, chromosomal instability; GS, genomic stability.

https://doi.org/10.1371/journal.pone.0270591.g001

Table 3. Etiology of mismatch repair dysfunction in gastric cancer after treatment for Hodgkin lymphoma.

| MSI t-GC case | MMR loss of staining | MSI       | MLH1 promoter   | Mutation analysis |
|--------------|----------------------|-----------|-----------------|-------------------|
| 1            | MLH1± PMS2± *        | MSS       | NE              |                   |
| 2            | MLH1- PMS2-          | MSI       | Methylated      |                   |
| 3            | MLH1- PMS2-          | MSI       | Methylated      |                   |
| 4            | MLH1- PMS2-          | MSI       | Methylated      |                   |
| 5            | MLH1- PMS2-          | MSI       | Not methylated  | Homozygous deletion including MLH1 |
| 6            | No loss, MMR+        | MSI       | Not methylated  | Double somatic MSH2 mutation† |
| 7            | MSH2- MSH6-          | MSI       | NE              | NE                |

Abbreviations: MMR, mismatch repair; MSI, microsatellite instability; MSS, microsatellite stability; NE, not evaluable.

* heterogeneous staining: partly clonal loss of staining, partly retained staining.

† Prediction of pathogenicity of MMR gene variant (benign, likely benign, uncertain, likely pathogenic or definitely pathogenic): MSH2(c.1511-1G>A), splice site mutation, definitely pathogenic; MSH2(c.2251G>A; p.G751R), definitely pathogenic. Both variants were detected at a rate of 20% in a tumor with 40% neoplastic cells.

https://doi.org/10.1371/journal.pone.0270591.t003

https://doi.org/10.1371/journal.pone.0270591.t003
explained by MLH1 promoter methylation. The fourth tumor had a complete loss of MLH1 and PMS2 staining and MLH1 promoter methylation was absent. A homozygous deletion in chromosome 3, comprising the MLH1 gene, was detected. This deletion was absent in normal tissue. The fifth MSI tumor showed proficient staining of all four MMR proteins and did not have a methylated MLH1 promoter. In this tumor, a double somatic mutation in MSH2 was detected. Germline DNA or normal tissue DNA was not available for this patient, but the levels of mutation detection indicated that these mutations were somatic: both variants were detected at a rate of 20% in a tumor with 40% neoplastic cells. The sixth tumor showed loss of MSH2 and MSH6 staining, but no further analyses could be performed due to insufficient DNA. A total of 32/90 (36%) t-GCs had strong nuclear p53 staining and were classified as sCIN, leaving 48/90 (53%) to be classified as sGS.

Associations of molecular subtypes with characteristics of gastric cancer

The age at t-GC diagnosis differed significantly between subtypes, with median ages for EBV, MSI, sCIN and sGS subtypes of 43, 71, 65 and 52 years, respectively (p < 0.001). When evaluating the frequency of molecular subtypes according to periods of t-GC diagnosis (Table 2), the frequency of the sGS subtype was 68% in the period 1990–1999, 54% in 2000–2009 and 44% in 2010–2015 (p = 0.27).

The frequency of sCIN in gastroesophageal junction t-GCs was 44% compared with 35% in the fundus and corpus, and 25% in antrum (p = 0.29, Fig 1). In contrast, the sGS subtype was particularly frequent in the antrum (61%), compared with 49% in the gastroesophageal junction and 47% in the fundus and corpus (p = 0.55). Intestinal type carcinomas were 2% EBV, 8% MSI, 43% sCIN and 47% sGS and diffuse type carcinomas were 6% EBV, 3% MSI, 22% sCIN and 69% sGS (p = 0.09).

Associations of gastric cancer molecular subtypes with characteristics of Hodgkin lymphoma or testicular cancer

In Hodgkin lymphoma survivors (n = 66), the subtype distribution was 3% EBV, 11% MSI, 32% sCIN and 55% sGS. (Table 4) In testicular cancer survivors (n = 24), no tumors of the MSI subtype were detected and the subtype distribution was 4% EBV, 46% sCIN and 50% sGS. We additionally evaluated period of diagnosis of Hodgkin lymphoma or testicular cancer and the association with t-GC subtypes. When Hodgkin lymphoma or testicular cancer was diagnosed before 1990, t-GC was more frequently sGS (63%) than when Hodgkin lymphoma or testicular cancer was diagnosed after 1990 (38%, p = 0.03). Only 4% of t-GCs were of the MSI subtype in Hodgkin lymphoma or testicular cancer patients diagnosed before 1990, compared with 15% in Hodgkin lymphoma or testicular cancer patients diagnosed after 1990 (p = 0.10).

In patients treated with abdominal radiotherapy, 70% of t-GCs were sGS, in contrast with 47% when no abdominal radiotherapy was given (p = 0.15). In t-GCs of patients treated with or without procarbazine/dacarbazine, no differences were seen in sGS frequency (57% vs. 60%, p = 0.80). In patients who received both abdominal radiotherapy and procarbazine/dacarbazine, 9/12 (75%) of t-GCs were of the sGS subtype.

Comparison of molecular subtypes in gastric cancer after treatment for Hodgkin lymphoma or testicular cancer with gastric cancer in the general population

The distribution of subtypes observed in t-GC were compared with published data on the distribution of subtypes in the general population (p-GC) that used the same methodology [27].
Baseline characteristics, including gender, TNM stage, tumor location and Lauren classification were comparable between t-GC and p-GC patients (S1 Table). Mean age at diagnosis, however, was 67 years in p-GC patients and 58 years in t-GC patients.

Overall subtype distribution was not significantly different between groups ($p = 0.10$, Fig 2). EBV was present in 3% of t-GCs and 7% p-GCs ($p = 0.34$) and MSI in 8% of t-GCs and 16% of p-GCs ($p = 0.07$). A total of 36% t-GC and 38% p-GCs were sCIN ($p = 0.68$). The only subtype with a significantly different distribution was sGS, which occurred more frequently in t-GCs (53%) than in p-GCs (38%, $p = 0.04$).

When evaluating subtype distribution among intestinal and diffuse types separately, no differences were present between t-GC and p-GC in intestinal type carcinomas ($p = 0.35$, Fig 2). In diffuse type carcinomas, however, the overall distribution in subtypes was different between t-GCs and p-GCs ($p = 0.02$). Specifically in diffuse type t-GCs, the MSI subtype was less frequent (3% vs. 24% in p-GC, $p = 0.03$), sGS was more frequent (69% vs. 39% in p-GC, $p = 0.03$), whereas EBV and sCIN frequencies were not different between groups.

Compared with p-GC, t-GCs located in the antrum were more frequently sGS (61% in t-GC vs. 28% in p-GC, $p = 0.02$), whereas EBV, MSI and sCIN frequencies were not different (EBV 4% vs. 8%, MSI 11% vs. 32%, sCIN 25% vs. 32%, overall test $p = 0.08$). The subtype...
Fig 2. Molecular subtype distribution of gastric cancer after treatment for Hodgkin lymphoma or testicular cancer and gastric cancer in the general population. A: overall comparison of molecular subgroup distributions between t-GC and p-GC. B: molecular subgroup comparison between t-GC and p-GC after selection of Lauren classification. C: molecular subgroup comparison between t-GC and p-GC after selection of gastric cancer location.

Abbreviations: EBV, Epstein-Barr virus; MSI, microsatellite instability; sCIN, surrogate chromosomal instability; sGS,
distribution of gastroesophageal junction and fundus or corpus t-GCs was not different from p-GCs (Fig 2).

Discussion

This is the first study that describes histopathologic and molecular characteristics of t-GC diagnosed in survivors of Hodgkin lymphoma and testicular cancer. This study was performed primarily to provide initial descriptive data to support future hypothesis-driven research. The main difference between t-GC and gastric adenocarcinoma in the general population is the higher frequency of the sGS subtype, especially within the subgroup of patients who had been treated for their Hodgkin lymphoma or testicular cancer before 1990. In this time period, treatments for Hodgkin lymphoma and testicular cancer were more intensive than in recent years, including higher doses and larger fields of radiotherapy (e.g. extensive abdominal fields) and higher cumulative doses of chemotherapy. Also, t-GCs located in the antrum, an area that receives significant irradiation doses, were more frequently sGS. This suggests an association of sGS adenocarcinoma with prior anticancer treatment. Due to a high degree of missing treatment data, we were not able to demonstrate clear associations of specific treatments with molecular subtypes of t-GC.

An increased frequency of MSI was not observed in t-GC compared with p-GC, unlike what has been observed in therapy-related colorectal cancer [21]. Still, within the small group of MSI t-GCs, double somatic MMR gene mutations could be detected in 2/7 tumors. As a high frequency of double somatic MMR gene mutations was detected in therapy-related colorectal cancer, this may reflect therapy-related carcinogenesis [21]. It can be mentioned that the somatic MMR gene mutations found in the two t-GCs were located outside so called coding poly-A tracts, which was reported as the primary location of somatic MMR gene mutations in sporadic gastric cancer [36]. The poly-A tracts, which are microsatellites that are also present within MMR genes, are highly sensitive to defective MMR. Mutations within these coding poly-A tracts are thought to represent a secondary change due to some other primary MMR dysfunction, such as MLH1 promoter methylation.

In one of the t-GCs of the MSI subtype, MMR deficiency was only detected in a part of the tumor biopsies. This could be a late event and not a driver event in carcinogenesis. However, only biopsy tissue was available which limited our assessment of the total contribution of MMR deficiency in this case. Therefore we decided to include this tumor in the MSI subtype. The etiology of MMR dysfunction could not be evaluated in this tumor due to limited tissue.

To our knowledge, the association of radiotherapy or alkylating agents with genomically stable gastric cancer, or diffuse type gastric cancer has not been evaluated previously. Several mouse models use alkylating agents as gastric carcinogens, frequently leading to well differentiated intestinal type tumors [18]. However, mouse models of diffuse type cancer also use alkylating agents as carcinogen [37]. In addition, irradiation has been associated with gastric carcinogenesis in mouse models [19]. In humans, the association of abdominal radiotherapy and gastric cancer risk is strong [2, 3, 9–11]. A supramultiplicative interaction of abdominal radiotherapy and alkylating agents with gastric cancer risk has been suggested [2]. Based on these studies, we are not able to assign either radiotherapy or alkylating agents as the major component to induce t-GC.
In our study, evaluations of separate or interactive effects of radiotherapy and/or alkylating agents on t-GC characteristics are limited by missing treatment data of Hodgkin lymphoma and testicular cancer patients. It can be hypothesized that radiotherapy is mainly associated with sGS t-GC, and alkylating agents to a lesser extent. To explain, sGS t-GC was present in a comparable frequency in testicular cancer and Hodgkin lymphoma survivors, and the increased gastric cancer risk in testicular cancer survivors is associated with radiotherapy only [9, 10, 12, 38]. Also, antral t-GCs were frequently of the sGS subtype and this region receives high radiotherapy doses (>30 Gy) after treatment with common fields for both Hodgkin lymphoma and testicular cancer [2, 10].

The selected general population cohort was chosen for comparison because of the the simplicity of the method of gastric cancer subtype evaluation and the comparable baseline characteristics of patients from a Western country. The comparison with this cohort also has several limitations. Firstly, the age difference between t-GCs and the general population cohort limited comparability. This difference is likely attributable to prior anticancer treatment, as the age of onset of therapy-related cancer is often lower than of sporadic cancer in the general population. However, comparison with a younger general population cohort would have given rise to a selective population that developed gastric cancer early due to genetic or environmental factors. Secondly, time periods of gastric cancer diagnosis may have influenced the results, as incidence rates of gastric cancer have changed over time, coinciding with a temporal increase in the proportion of diffuse type and a decrease in the proportion of intestinal type carcinomas. Although the years of diagnosis of gastric cancer in the general population cohort were not reported, a subset of our t-GCs was probably diagnosed earlier, as they were diagnosed between 1982 and 2015 [39]. Thirdly, the methods in our study and in the comparison cohort result in data that are poorly comparable with other studies, except for EBV and MSI analyses (S2 Table) [23–27]. The use of p53 IHC to distinguish between chromosomal instability and genomic stability is debatable, as TP53 mutations were present in 71% of chromosomally unstable tumors and in approximately 10% of genomically stable tumors within the TCGA set [23]. However, elevated expression of p53 (reverse phase protein array) was suggestive of TP53 mutations and associated with the chromosomal instability subtype of TCGA tumors. Based on the strong association with missense TP53 mutations, the definition of aberrant p53 IHC (e.g. the widespread staining of at least 70% of tumor nuclei) was chosen in the comparison cohort [40].

Another limitation of this study is the absence of data on risk factors for gastric cancer, including genetic factors and lifestyle. Also, as reported relative risks of gastric cancer after Hodgkin lymphoma or testicular cancer range from 3–10, leading to an attributable risk of 67–90% ((relative risk–1)/relative risk), approximately 10–33% of our t-GCs are not attributable to prior anticancer treatment but are indeed sporadic [2–4, 9, 10, 41].

The high frequency of the sGC subtype in t-GCs was not explained in our study. There may be (therapy-related) aberrations in these tumors that are specific for these t-GCs. More extensive molecular analyses should be performed to clarify these differences. This was not feasible in this study due a small sample size and material restrictions. These future studies should evaluate therapy-specific aberrations as potential treatment targets. In addition, the molecular characteristics of t-GC should be taken into account when considering the widely discussed options for gastric cancer surveillance in high-risk populations such as survivors of Hodgkin lymphoma and testicular cancer [42, 43].

In conclusion, t-GCs were more frequently classified as sGS subtype compared with p-GC. The pathogenesis of these t-GCs of the sGS subtype remains unknown. The frequency of sGS is higher in t-GC patients who were treated for Hodgkin lymphoma or testicular cancer treatment in an earlier (<1990) time period, when this treatment was more intensive. In contrast
with therapy-related colorectal cancer, the frequency of MSI t-GCs was not increased. However, double somatic MMR gene mutations were detected in two out of seven t-GCs of the MSI subtype. These results suggest that at least a subset of t-GCs may have a different pathogenesis than gastric cancer in the general population.

Supporting information
S1 Table. Baseline characteristics gastric cancer after treatment for Hodgkin lymphoma or testicular cancer and gastric cancer in the general population. (DOCX)
S2 Table. Distribution of gastric cancer subtypes in literature according to tumor location and Lauren classification. (DOCX)
S1 Fig. CONSORT diagram of gastric cancer patients after treatment for Hodgkin lymphoma or testicular cancer. (DOCX)

Acknowledgments
We would like to acknowledge the NKI-AVL Core Facility Molecular Pathology & Biobanking (CFMPB), especially Sten Cornelissen, for supplying NKI-AVL Biobank material and/or lab support. We would also like to thank Koen van de Vijver for insights into immunohistochemical analyses, Mohamed Achahchah for technical assistance, and all participating laboratories for the distribution of the t-GC material. We would like to thank the members of the PALGA group: L. Arensman, J.D. Burggraaf, G. van Ingen, J.W.R. Meijer, S.L. Meijer, S.H. Sastrowijoto. Finally, we would like to thank Winand Dinjens and Peggy Atmodimedjo for performing the somatic MMR gene mutation analyses and Hein te Riele for the thorough review of the manuscript.

Author Contributions
Conceptualization: Lisanne S. Rigter, Petur Snaebjornsson, Efraim H. Rosenberg, Berthe M. P. Aleman, Lindsay Morton, Gerrit A. Meijer, Flora E. van Leeuwen, Monique E. van Leerdam.
Data curation: Lisanne S. Rigter, Petur Snaebjornsson, Efraim H. Rosenberg, Estelle Altena, Michael Schaapveld, Gerrit A. Meijer.
Formal analysis: Lisanne S. Rigter, Petur Snaebjornsson.
Funding acquisition: Monique E. van Leerdam.
Investigation: Lisanne S. Rigter, Efraim H. Rosenberg, Estelle Altena, Nicole C. T. van Grie-ken, Berthe M. P. Aleman, Jan M. Kerst, Michael Schaapveld.
Methodology: Lisanne S. Rigter, Efraim H. Rosenberg.
Project administration: Lisanne S. Rigter.
Software: Gerrit A. Meijer.
Supervision: Jan M. Kerst, Lindsay Morton, Flora E. van Leeuwen, Monique E. van Leerdam.
Writing – original draft: Lisanne S. Rigter.
Writing – review & editing: Petur Snaebjornsson, Estelle Altena, Nicole C. T. van Grieken, Berthe M. P. Aleman, Jan M. Kerst, Michael Schaapveld, Gerrit A. Meijer, Flora E. van Leeuwen, Monique E. van Leerdam.

References

1. Gilbert ES, Curtis RE, Hauptmann M, et al. Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects. *Radiat Res* 2017; 187:186–195. https://doi.org/10.1667/RR14453.1 PMID: 28118119

2. Morton LM, Dores GM, Curtis RE, et al. Stomach cancer risk after treatment for Hodgkin lymphoma. *J Clin Oncol* 2013; 31:3369–77. https://doi.org/10.1200/JCO.2013.50.6832 PMID: 23980092

3. Birdwell SH, Hancock SL, Varghese A, et al. Gastrointestinal cancer after treatment of Hodgkin’s disease. *Int J Radiat Oncol Biol Phys* 1997; 37:67–73. https://doi.org/10.1016/s0360-3016(96)00489-0 PMID: 9054878

4. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. *J Clin Oncol* 2007; 25:1489–97. https://doi.org/10.1200/JCO.2006.09.0936 PMID: 17372278

5. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma. *N Engl J Med* 2015; 373:2499–511. https://doi.org/10.1056/NEJMoa1505949 PMID: 26699166

6. Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. *Blood* 2002; 100:1989–96. https://doi.org/10.1182/blood-2002-02-0634 PMID: 12200357

7. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. *J Clin Oncol* 2000; 18:498–509. https://doi.org/10.1200/JCO.2000.18.3.498 PMID: 10653865

8. Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. *J Clin Oncol* 2000; 18:2435–43. https://doi.org/10.1200/JCO.2000.18.12.2435 PMID: 10956104

9. van den Belt-Dusebout AW, Aleman BM, Besseling G, et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. *Int J Radiat Oncol Biol Phys* 2009; 75:1420–9. https://doi.org/10.1016/j.ijrobp.2009.01.073 PMID: 19931732

10. Hauptmann M, Fossa SD, Stovall M, et al. Increased stomach cancer risk following radiotherapy for testicular cancer. *Br J Cancer* 2015; 112:44–51. https://doi.org/10.1038/bjc.2014.552 PMID: 25949972

11. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. *J Natl Cancer Inst* 2005; 97:1354–65. https://doi.org/10.1093/jnci/dji278 PMID: 16174857

12. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. *J Clin Oncol* 1993; 11:415–24. https://doi.org/10.1200/JCO.1993.11.3.415 PMID: 8445415

13. Tukenova M, Diallo I, Anderson H, et al. Second malignant neoplasms in digestive organs after childhood cancer: a cohort-nested case-control study. *Int J Radiat Oncol Biol Phys* 2012; 82:e383–90. https://doi.org/10.1016/j.ijrobp.2011.05.069 PMID: 22284034

14. Kleinerman RA, Smith SA, Holowaty E, et al. Radiation dose and subsequent risk for stomach cancer in long-term survivors of cervical cancer. *Int J Radiat Oncol Biol Phys* 2013; 86:922–9. https://doi.org/10.1016/j.ijrobp.2013.04.016 PMID: 23707149

15. Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. *J Natl Cancer Inst* 2007; 99:1634–43. https://doi.org/10.1093/jnci/djm201 PMID: 17971527

16. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. *J Clin Oncol* 2002; 20:3484–94. https://doi.org/10.1200/JCO.2002.09.038 PMID: 12177110

17. Youn P, Li H, Milano MT, et al. Long-term survival among Hodgkin’s lymphoma patients with gastrointestinal cancer: a population-based study. *Ann Oncol* 2013; 24:202–8. https://doi.org/10.1093/annonc/mds218 PMID: 22855552

18. Hayakawa Y, Fox JG, Gonda T, et al. Mouse models of gastric cancer. *Cancers (Basel)* 2013; 5:92–130. https://doi.org/10.3390/cancers5010092 PMID: 24216700
19. Trani D, Nelson SA, Moon BH, et al. High-energy particle-induced tumorigenesis throughout the gastrointestinal tract. *Radiat Res* 2014; 181:162–71. https://doi.org/10.1667/RR13502.1 PMID: 24512616

20. Hayakawa Y, Jin G, Wang H, et al. CCK2R identifies and regulates gastric antral stem cell states and carcinogenesis. *Gut* 2015; 64:544–53. https://doi.org/10.1136/gutjnl-2014-307190 PMID: 24951258

21. Rigter LS, Snaebjornsson P, Rosenberg EH, et al. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment. *Gut* 2016; Published Online First: November 8, 2016 https://doi.org/10.1136/gutjnl-2016-312608 PMID: 29439113

22. Boldrin E, Rumiato E, Fassan M, et al. Genetic features of metachronous esophageal cancer developed in Hodgkin's lymphoma or breast cancer long-term survivors: an exploratory study. *PLoS One* 2015; 10:e0117070. https://doi.org/10.1371/journal.pone.0117070 PMID: 25611972

23. Cancer Genome Atlas Research. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014; 513:202–9. https://doi.org/10.1038/nature13480 PMID: 25079317

24. Cristescu R, Lee J, Nebozyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. *Nature Medicine* 2015; 21:449–56. https://doi.org/10.1038/nm.3850 PMID: 25894828

25. Ahn S, Lee SJ, Kim Y, et al. High-throughput Protein and mRNA Expression-based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications. *Am J Surg Pathol* 2017; 41:106–115. https://doi.org/10.1097/PAS.0000000000001756 PMID: 27819872

26. Setia N, Agoston AT, Han HS, et al. A protein and mRNA expression-based classification of gastric cancer. *Mod Pathol* 2016; 29:772–84. https://doi.org/10.1038/modpathol.2016.55 PMID: 27032689

27. Gonzalez RS, Messing S, Tu X, et al. Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma. *Hum Pathol* 2016; 56:16–21. https://doi.org/10.1016/j.humpath.2016.06.003 PMID: 27342907

28. Cancer Genome Atlas Research. Integrated genomic characterization of oesophageal carcinoma. *Nature* 2017; 541:169–175. https://doi.org/10.1038/nature20805 PMID: 28052061

29. Lauren P. The Two Histologic Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. *Acta Pathol Microbiol Scand* 1965; 64:31–49. https://doi.org/10.1111/apm.1965.64.1.31 PMID: 14320675

30. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. *J Clin Oncol* 2007; 25:4370–8. https://doi.org/10.1200/JCO.2006.10.5296 PMID: 17906202

31. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. *J Clin Oncol* 2003; 21:3431–9. https://doi.org/10.1200/JCO.2003.07.131 PMID: 12865835

32. van Eggermond AM, Schaapveld M, Lugtenburg PJ, et al. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. *Blood* 2014; 124:319–27. https://doi.org/10.1182/blood-2013-10-532184 PMID: 24740811

33. Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in the Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. *Cell Oncol* 2007; 29:19–24. https://doi.org/10.1155/2007/971816 PMID: 17429138

34. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. *Br J Surg* 1998; 85:1457–9. https://doi.org/10.1046/j.1365-2168.1998.00940.x PMID: 9823902

35. International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System 4th edition 2010.

36. Pinto M, Wu Y, Mensink RG, et al. Somatic mutations in mismatch repair genes in sporadic gastric carcinomas are not a cause but a consequence of the mutator phenotype. *Cancer Genet Cytogenet* 2008; 180:110–4. https://doi.org/10.1016/j.cancergenety.2007.09.022 PMID: 18206535

37. Humar B, Blair V, Charfton A, et al. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. *Cancer Res* 2009; 69:2050–6. https://doi.org/10.1158/0008-5472.CAN-08-2457 PMID: 19223545

38. Fung C, Fossa SD, Milano MT, et al. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. *J Clin Oncol* 2013; 31:3807–14. https://doi.org/10.1200/JCO.2013.59.3409 PMID: 24043737

39. Wu H, Rusiecki JA, Zhu K, et al. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. *Cancer Epidemiol Biomarkers Prev* 2009; 18:1945–52. https://doi.org/10.1158/1055-9965.EPI-09-0250 PMID: 19531677
40. Ando K, Oki E, Saeki H, et al. Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer. *Cancer Med* 2015; 4:75–83. https://doi.org/10.1002/cam4.346 PMID: 25354498

41. van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. *J Clin Oncol* 2000; 18:487–97. https://doi.org/10.1200/JCO.2000.18.3.487 PMID: 10653864

42. Sugimoto S, Komatsu H, Morohoshi Y, et al. Recognition of and recent issues in hereditary diffuse gastric cancer. *J Gastroenterol* 2015; 50:831–43. https://doi.org/10.1007/s00535-015-1093-9 PMID: 26049741

43. Kim GH, Liang PS, Bang SJ, et al. Screening and surveillance for gastric cancer in the United States: Is it needed? *Gastrointest Endosc* 2016; 84:18–28. https://doi.org/10.1016/j.gie.2016.02.028 PMID: 26940296